Emyria Secures Exclusive Brisbane Clinic, Expands National Mental Health Reach
Emyria has inked a pivotal agreement with Avive Health to launch its first Empax clinic in Queensland, expanding its innovative mental health treatment network. This move builds on its recent Medibank partnership, advancing accessible, reimbursed care for treatment-resistant conditions.
- Exclusive Empax clinic established in Brisbane’s Avive Health hospital
- First right of refusal for expansion into Victoria and South Australia
- Partnership supports capital-light, scalable national rollout strategy
- Focus on reimbursed psychedelic-assisted therapies for PTSD and depression
- Clinic launch targeted for Q4 2025 following regulatory approvals
Emyria’s Strategic Expansion into Queensland
Emyria Limited, a frontrunner in innovative mental health treatments, has announced a landmark agreement with Avive Health to establish its first Empax clinic in Queensland. Located within Avive’s licensed private hospital in Brisbane, this clinic marks a significant milestone in Emyria’s national expansion strategy, following closely on the heels of its recent multi-year agreement with Medibank Private Ltd.
The Brisbane clinic will exclusively deliver Emyria’s Empax programs targeting post-traumatic stress disorder (PTSD) and treatment-resistant depression, two of Australia’s most pressing mental health challenges. This partnership not only broadens patient access to reimbursed, psychedelic-assisted therapies but also integrates Emyria’s care protocols directly into Avive’s hospital workflows, ensuring seamless clinical delivery.
Capital-Light Growth and National Ambitions
Emyria’s approach emphasizes scalable, capital-light expansion through strategic partnerships with private hospitals. The agreement grants Emyria exclusive rights at the Brisbane site and a first right of refusal for clinics in Victoria and South Australia, positioning the company to rapidly extend its footprint across eastern Australia.
With mental health conditions like PTSD affecting approximately one in eleven Australians, and existing healthcare systems struggling to meet demand, Emyria’s model addresses a critical gap. By leveraging reimbursed, evidence-based psychedelic-assisted therapies, the company aims to transform access to effective mental health care while maintaining operational efficiency.
Looking Ahead – Launch and Impact
The Brisbane Empax clinic is slated to commence treatment in the fourth quarter of 2025, pending regulatory approvals and facility fit-out completion. This timeline aligns with Emyria’s broader vision to establish additional clinics in major metropolitan areas, deepen insurer and hospital collaborations, and expand treatment indications beyond PTSD and depression.
Executives from both companies expressed optimism about the partnership’s potential. Emyria’s Executive Chairman Greg Hutchinson highlighted the deal as a key step in scaling innovative mental health care nationally, while Avive’s Co-CEO Mark Sweeney emphasized their shared commitment to setting new standards for patient-centered, outcomes-driven treatment.
As Emyria continues to build on its reimbursement breakthroughs and clinical partnerships, the mental health sector will be watching closely to see how this model reshapes treatment accessibility and efficacy in Australia.
Bottom Line?
Emyria’s Queensland clinic deal signals a new chapter in accessible, reimbursed mental health care across Australia.
Questions in the middle?
- How quickly will Emyria secure regulatory approvals to begin treatments in Brisbane?
- What financial impact will this partnership have on Emyria’s growth trajectory?
- Will the Empax model expand to other mental health conditions beyond PTSD and depression?
